Preservation of healthy lean body mass and function during weight loss

Clinical ObesityEarly View e12683 CORRESPONDENCE Preservation of healthy lean body mass and function during weight loss T. J. Wilkinson, Corresponding Author T. J. Wilkinson [email protected] orcid.org/0000-0002-7855-7752 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UK Correspondence T. J. Wilkinson, NIHR Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, University of Leicester, Leicester LE54PW, UK. Email: [email protected]Search for more papers by this authorD. Papamargaritis, D. Papamargaritis orcid.org/0000-0001-5044-1515 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorJ. A. King, J. A. King orcid.org/0000-0002-8174-9173 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UK School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UKSearch for more papers by this authorJ. A. Sargeant, J. A. Sargeant orcid.org/0000-0003-0395-7329 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorC. Sutcliffe, C. Sutcliffe Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorL. A. Baker, L. A. Baker orcid.org/0000-0003-2111-3832 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorS. Taheri, S. Taheri Department of Medicine, Weill Cornell Medicine Qatar, Doha, Qatar Hamad Medical Corporation, Doha, QatarSearch for more papers by this authorT. Yates, T. Yates orcid.org/0000-0002-5724-5178 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorM. J. Davies, M. J. Davies orcid.org/0000-0002-9987-9371 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this author T. J. Wilkinson, Corresponding Author T. J. Wilkinson [email protected] orcid.org/0000-0002-7855-7752 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UK Correspondence T. J. Wilkinson, NIHR Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, University of Leicester, Leicester LE54PW, UK. Email: [email protected]Search for more papers by this authorD. Papamargaritis, D. Papamargaritis orcid.org/0000-0001-5044-1515 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorJ. A. King, J. A. King orcid.org/0000-0002-8174-9173 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UK School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UKSearch for more papers by this authorJ. A. Sargeant, J. A. Sargeant orcid.org/0000-0003-0395-7329 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorC. Sutcliffe, C. Sutcliffe Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorL. A. Baker, L. A. Baker orcid.org/0000-0003-2111-3832 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorS. Taheri, S. Taheri Department of Medicine, Weill Cornell Medicine Qatar, Doha, Qatar Hamad Medical Corporation, Doha, QatarSearch for more papers by this authorT. Yates, T. Yates orcid.org/0000-0002-5724-5178 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this authorM. J. Davies, M. J. Davies orcid.org/0000-0002-9987-9371 Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester, UKSearch for more papers by this author First published: 23 May 2024 https://doi.org/10.1111/cob.12683Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Pinkney J, Tarrant M. Time for a new agenda for behavioural treatment of overweight and obesity. Clin Obes. 2024; 14:e12628. 10.1111/cob.12628 PubMedWeb of Science®Google Scholar 2Blundell JE, Gibbons C, Beaulieu K, et al. The drive to eat in homo sapiens: energy expenditure drives energy intake. Physiol Behav. 2020; 219:112846. 10.1016/j.physbeh.2020.112846 CASPubMedWeb of Science®Google Scholar 3Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017; 8(3): 511-519. 10.3945/an.116.014506 CASPubMedWeb of Science®Google Scholar 4Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab. 2019; 34(3): 247-262. 10.3803/EnM.2019.34.3.247 CASGoogle Scholar 5Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-216. 10.1056/NEJMoa2206038 CASPubMedWeb of Science®Google Scholar 6Kushner R, Aronne L, Stefanski A, et al. Tirzepatide-induced weight loss is associated with body composition improvements across age groups. Obesity. 2022; 30:49. Google Scholar 7Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989-1002. 10.1056/NEJMoa2032183 CASPubMedWeb of Science®Google Scholar 8Wadden TA, Chao AM, Moore M, et al. The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities. Curr Obes Rep. 2023; 12: 453-473. 10.1007/s13679-023-00534-z PubMedWeb of Science®Google Scholar 9Oppert JM, Bellicha A, van Baak MA, et al. Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. Obes Rev. 2021; 22(suppl 4):e13273. 10.1111/obr.13273 PubMedGoogle Scholar 10Yates T, Sargeant JA, King JA, et al. Initiation of new glucose-lowering therapies may act to reduce physical activity levels: pooled analysis from three randomized trials. Diabetes Care. 2022; 45(11): 2749-2752. 10.2337/dc22-0888 CASPubMedWeb of Science®Google Scholar 11Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021; 4(1):e2033457. 10.1001/jamanetworkopen.2020.33457 PubMedWeb of Science®Google Scholar 12Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023; 402(10403): 720-730. 10.1016/S0140-6736(23)01163-7 CASPubMedWeb of Science®Google Scholar 13Gydesen S, Hjuler ST, Freving Z, et al. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017; 174(7): 591-602. 10.1111/bph.13723 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issuee12683 ReferencesRelatedInformation